

COLLEGE of AMERICAN PATHOLOGISTS


# Get Ready for the PT CLIA Changes: Stay Ahead, Stay Compliant

**CAP** Webinar


June 27, 2024



### **Regulatory Changes Impacting Laboratories**



• Webinar Focus: CLIA Proficiency Testing (PT) Changes • Changes go into effect Jan. 1, 2025



### **Today's Presenters**

- Jonathan Genzen, MD, PhD, FCAP
  - Chair, CAP Clinical Chemistry Committee



- Christi Wojewoda, MD, FCAP
  - Chair, CAP Microbiology Committee



### P Committee





- **Upcoming Regulatory Changes** •
- **Background: CLIA PT Updates**  $\bullet$
- **High Level Overview of Non-Microbiology Changes**  $\bullet$
- **Tools to Prepare for Changes: PT Participation/Evaluation Reports**
- **Examples**  $\bullet$
- **Impact on CAP PT Enrollment**  $\bullet$





# **Upcoming Regulatory Changes**

© College of American Pathologists.

## **Regulatory Changes Impacting Laboratories**

- Today's Focus: CLIA Proficiency Testing (PT) Changes
  - Changes go into effect Jan. 1, 2025 Ο
- **Impacted Specialties:** 
  - **Microbiology** 0
  - Chemistry 0
  - **Diagnostic Immunology** 0
  - Hematology (including routine hematology and coagulation) 0
  - Immunohematology 0



# **Other Regulatory Changes Impacting Laboratories** (Continued)

- Final Rule CLIA Fees, Histocompatibility, Personnel, and Alternative Sanctions for Certificate of Waiver Laboratories (CMS-3326-F)
  - **Effective Dec. 28, 2024**  $\bigcirc$
  - 2024 CAP checklist edition expected to publish in October/November to incorporate CLIA changes
  - Laboratories must continue to follow their current checklist edition until that time  $\bigcirc$
  - Learn about 2024 checklist changes: Nov. 20th Focus on Compliance webinar, "Staying in Sync: CAP 0 **Accreditation Checklist Changes for 2024**"



# **Other Regulatory Changes Impacting Laboratories** (Continued)

- Final FDA Oversight of Laboratory Developed Test (LDT) Regulation
  - Follow CAP Advocacy updates (cap.org/advocacy)



26 June 2024

8

# **Background: CLIA PT Updates**

© College of American Pathologists.

## **Background: Update Rationale**

- CLIA '88 regulations were published in subpart I of the Federal Register on February 28, 1992
- Since 1992, the testing has evolved significantly; current technology is more accurate and precise
- The HHS solicited input from the Clinical Laboratory Improvement Advisory Committee (CLIAC), the official federal advisory committee responsible for advising HHS on regulatory standards for ensuring accuracy and reliability of laboratory testing.

## **Background: Update Rationale (Continued)**

- CMS and the CDC collaborated in revising the required analytes and published a proposed rule on February 4, 2019
- PT changes: whether addition of new analytes, deletion of analytes, or changes in acceptance limits, apply to analytes listed in subpart I of the Federal Register.



## **PT Changes: Specialty and Subspecialty**

CMS finalized the 29 non-micro analytes based on factors:

- Current availability of PT materials
- Number of PT programs currently offering PT
- Volume of patient testing performed nationwide 0
- Impact on patient health, cost, and feasibility of implementation Ο

### • Some potential analytes for inclusion were not pursued:

- Too unstable for PT development or shipping, or  $\bigcirc$
- Methodology was not sufficiently standardized to support PT (ex: Vitamin D testing)  $\bigcirc$

## **PT Changes: Specialty and Subspecialty**

### §493.909 Microbiology

- §493.911 Bacteriology
- §493.913 Mycobacteriology
- §493.915 Mycology
- §493.917 Parasitology
- > §493.919 Virology

### §493.921 Diagnostic Immunology

- ≽§493.923 Syphilis serology
- ≽§493.927 General immunology

## PT Changes: Specialty and Subspecialty (Continued)

### §493.929 Chemistry

- §493.931 Routine chemistry
- §493.933 Endocrinology
- §493.937 Toxicology

§493.941 Hematology (including routine Hematology and Coagulation)

§493.959 Immunohematology



# **High Level Non-Microbiology Changes**

© College of American Pathologists.

## **New Regulated Analytes**

- 29 new analytes/tests for which PT will be required
- Many analytes for which PT was not required are now in routine clinical
  - use, (e.g.) Hemoglobin A1c, troponins
    - High sensitivity troponins are preferred, but are 0 not CMS regulated

CLIA regulation	New analytes
General immunology §493.927	Anti-HBs Anti-HCV C-reactive protein (high sensitivity)
Routine chemistry §493.931	B-natriuretic peptide (BNP) ProBNP Cancer antigen (CA) 125 Carbon dioxide Carcinoembryonic antigen Cholesterol, low density lipoprotein, direct measurement Ferritin Gamma glutamyl transferase Hemoglobin A1c Phosphorus Prostate specific antigen, total Total iron binding capacity (TIBC), direct measurement Troponin I Troponin T
Endocrinology §493.933	Estradiol Folate, serum Follicle stimulating hormone Luteinizing hormone Progesterone Prolactin Parathyroid hormone Testosterone Vitamin B12
Toxicology §493.937	Acetaminophen, serum Salicylate Vancomycin

## **Removed Analytes From Subpart I**

- Five analytes/tests are removed from Subpart I of the Federal Register
  - Lactate dehydrogenase (LDH) isoenzymes Ο
  - **Ethosuximide**  $\bigcirc$
  - **Primidone** Ο
  - Quinidine  $\bigcirc$
  - **Procainamide (and its metabolite N-acetyl procainamide)** 0

## **Alternative Performance Assessment**

- At least 2x/year, laboratories must verify the accuracy of any test or procedure it performs that is not included in subpart I of the Federal Register
- The CAP will continue to offer the deleted, non-CMS regulated analytes in its current PT programs as participation in PT is one of the ways to meet this regulatory requirement

## **Grading Changes**

- 53 analytes/tests (existing or new) for which percentage-based acceptance limits are published
- White blood cell differential is the only test with standard deviation, as there were no biological variability data available

- See tables with all grading changes at cap.org.
  - Search: regulatory news and updates

# **Grading Changes (Continued)**

- Per CMS: tightening limits may increase miss rates per challenge
  - High unsuccessful rates not expected based on the data simulations provided by the PT programs
- As in the past, laboratories must get 4/5 challenges correct (80%) or the event will be considered unsatisfactory, except for immunohematology

### enge y the PT programs 80%) or the ematology

## **A Few Notable Grading Changes**

Analyte/Test	Current CMS criteria	New Criteria	Change
Hematocrit (Excluding spun hematocrit)	Target value ±6%	Target value ±4%	33.3%
Hemoglobin	Target value ±7%	Target value ±4%	~ 43%
Uric acid	Target value ±17%	Target value ±10%	41.1%
Magnesium	Target value ±25%	Target value ±15%	40%
Potassium	Target value ±0.5 mmol/L	Target value ±0.3 mmol/L	40%
Alpha- fetoprotein (AFP)	Target value <u>+</u> 3 SD	Target value <u>+</u> 20%	
pO2	Target value <u>+</u> 3SD	Target value <u>+</u> 15% or 15 mmHg (greater)	



# **Discipline-Specific Changes: Hematology**

Updated CLIA PT Regulations Set for January 1, 2025 Implementation

While the final rule is effective July 11, 2024, per CMS' directive, the implementation date for the laboratories and PT program providers for these revisions will be January 1, 2025, which is in alignment with its current process for PT program providers and PT enrollment.

### 2025 Criteria for Acceptable Performance

Analyte or test	Current CMS or CAP criteria for acceptable performance	New CMS or CAP criteria for acceptable performance to be implemented on January 1, 2025	Comments		
White blood cell (WBC) differential: Granulocytes Lymphocytes Monocytes Eosinophils Basophils	Target value ± 3 SD based on the percentage of different types of WBC in the specimens	Target value ± 3 SD based on the percentage of different types of WBC in the specimens	No change *See below for 2024 PT participation **See below for 2025 PT participation		
Hematocrit	ematocrit Target value ± 6% Target		Criteria changed		
Microhematocrit, waived	icrohematocrit, waived Target value ± 6% or ± 2 SD (greater)		No change		
Hemoglobin	Target value ± 7%	Target value ± 4%	Criteria changed		
MCV	Target value ± 3 SD	Target value ± 3 SD	No change		
MCH	Target value ± 3 SD	Target value ± 3 SD	No change		
MCHC	Target value ± 3 SD	Target value ± 3 SD	No change		
MPV	Target value ± 3 SD	Target value ± 3 SD	No change		
Nucleated red blood cell count (nRBC)	Educational	Educational	No change		
Platelet count	Target value ± 25%	Target value ± 25%	No change		
RDW	Target value ± 3 SD	Target value ± 3 SD	No change		
Red blood cell count	Target value ± 6%	Target value ± 4%	Criteria changed		
WBC count	Target value ± 15%	Target value ± 10%	Criteria changed		

Analytes regulated for proficiency testing appear in **bold** type.

\*For the 2024 calendar year, blood cell identification results are included in the CMS performance summary. In the event that blood cell identification (BCP or BCPV) is not performed, results from the flow through differential will be reported.

Per CMS, effective January 1, 2025, laboratories performing both a manual cell identification and an automated WBC differential must enroll in proficiency testing for both (BCP or BCPV and FH10). Scores for both will be submitted to CMS.

- Hematology: laboratories performing manual cell identification and an automated WBC differential must enroll in **PT** for both
  - The CAP will submit both scores to the CMS  $\bigcirc$
  - For example, BCP or BCPV and FH10 will both be 0 submitted to CMS.

© 2024 College of American Pathologists

26	June
-	2024

## **Discipline-Specific Changes: Coagulation**

- Coagulation: criterion for prothrombin time reporting units: seconds or the international normalized ratio (INR)
  - Laboratories must report PT the same way they report 0 patient results

Analyte or test	Current CMS or CAP criteria for acceptable performance	New CMS or CAP criteria for acceptable performance to be implemented on January 1, 2025	Comments		
Activated partial thromboplastin time	Target value ± 15%	Target value ± 15%	No change		
D-dimer, quant	Target value ± 3 SD	Target value ± 3 SD	No change No change		
Fibrinogen	Target value ± 20%	Target value ± 20%			
Prothrombin time	Prothrombin time target value ± 15% (CMS)	Prothrombin time target value ± 15% (CMS)	No change		
(seconds or international normalized ratio [INR])	INR target value ± 20% (CAP)	INR target value ± 15% (CMS)	Criteria changed for INR, see below for reporting*		
analytes regulated for profic	iency testing appear in <b>bol</b> d	type.	di -		

### 2025 Criteria for Acceptable Performance

For the 2024 calendar year, CAP criteria will be used for INR at target value ± 20%

## **Discipline-Specific Changes: Transfusion Medicine**

- Transfusion medicine: effective Jan. 1, 2025; unexpected antibody detection will no longer use 80% for satisfactory performance
  - Like ABO, Rh, and compatibility testing, 100% accuracy will be needed for unexpected antibody 0 detection. Antibody identification will remain at 80%+ accuracy.



### **Tools to Prepare for Changes** PT Participant Summary & Evaluation Reports

© College of American Pathologists.

## **PT Participant Summary & Evaluation Reports**

- All new analytes, criteria changes by specialty/subspecialty are included in each PT Participant Summary (PS) of all 2024 A-Mailing CMS regulated programs.
  - CAP will continue to provide this information throughout 2024

### Updated CLIA PT Regulations Set for January 1, 2025 Implementation

While the final rule is effective July 11, 2024, per CMS' directive, the implementation date for the laboratories and PT program providers for these revisions will be January 1, 2025, which is in alignment with its current process for PT program providers and PT enrollment.

### 2025 Criteria for Acceptable Performance

Analyte or test	Current CMS or CAP criteria for acceptable performance	New CMS or CAP criteria for acceptable performance to be implemented on January 1, 2025	Comments					
Whole blood cell (WBC) differential: Basophils Eosinophils Granulocytes Lymphocytes Monocytes	ifferential: based on the percentage of different types of WBC in the specimens symphocytes		No change *See below for 2024 PT participation **See below for 2025 PT participation					
Hematocrit	Target value ± 6%	Target value ± 4%	Criteria changed					
Microhematocrit, waived	crohematocrit, waived Target value ± 6% or ± 2 SD (greater)		No change					
Hemoglobin	Target value ± 7%	Target value ± 4%	Criteria changed					
Immoturo aronulocuto (IC)	Educational	Educational	No chango					

# **PT Participant Summary & Evaluation Reports** (Continued)

- Review Your PT **Evaluation Reports** for Quantitative PT **Programs** 
  - **Evaluation report lists** 0 laboratory's result, statistics for peer group, and normalized results as the standard deviation index (SDI).


COLLEGE of AMERICAN PATHOLOGISTS 325 Waukegan Road, Northfield, Illinois 60093-2750 800-323-4640 • cap.org		In: A	Number: stitution: ttention: y / State:						Or	igi
EVALUA					C	-C 202	1 Gen	eral Ch	emistry/T	'n
ORIGINA	L							ciai Gin	chilistry/ I	
Test Unit of Measure		Е	valuation a	ind Comp	arative					Ŧ
Peer Group		Your			No. of	1	imits of A	cceptabili	ty Your	L
- cci dioap	Specimen	Result	Mean	S.D.	Labs	S.D.I	Lower	Upper	Grade	L
Albumin	CHM-11	3.7	3.44	0.09	109	+3.0	3.0	3.8	Acceptable	Т
g/dL	CHM-12	3.1	2.95	0.09	110	+1.6	2.6	3.3	Acceptable	
DYE BINDING-BCG	CHM-13	5.0	4.85	0.09	107	+1.7	4.3	5.4	Acceptable	
ROCHE COBAS c311	CHM-14	3.1	2.93	0.08	109	+2.0	2.6	3.3	Acceptable	
	CHM-15	2.0	1.65	0.06	106	+5.7	1.4	1.9	Unacceptable	
Alkaline Phosphatase	CHM-11	377	365.8	14.6	118	+0.8	256	476	Acceptable	+
U/L	CHM-12	178	173.1	7.1	118	+0.7	121	226	Acceptable	L
ROCHE COBAS c311	CHM-13	241	235.2	9.2	118	+0.6	164	306	Acceptable	L
ROCHE	CHM-14	177	172.7	7.3	118	+0.6	120	225	Acceptable	L
	CHM-15	51	50.3	2.2	118	+0.3	35	66	Acceptable	
Amylase, serum	CHM-11	371	334.0	5.9	58	+6.2	233	435	Acceptable	t
U/L	CHM-12	161	158.8	2.1	57	+1.1	111	207	Acceptable	L
ROCHE COBAS c311	CHM-13	229	232.3	3.6	58	-0.9	162	302	Acceptable	L
ROCHE	CHM-14	159	158.4	2.3	58	+0.3	110	206	Acceptable	
	CHM-15	33	30.0	0.7	57	+4.2	20	39	Acceptable	
AST (SGOT)	CHM-11	235	241.3	9.0	107	-0.7	193	290	Acceptable	$^{+}$
U/L	CHM-12	103	106.6	4.5	107	-0.8	85	128	Acceptable	
ROCHE COBAS c311	CHM-13	148	160.2	7.2	106	-1.7	128	193	Acceptable	
ROCHE	CHM-14	105	107.8	5.0	108	-0.6	86	130	Acceptable	
	CHM-15	9	9.3	0.6	107	-0.5	7	12	Acceptable	



Kit Mailed: 9/27/2021

inal Evaluation: 11/3/2021

### nerapeutic Drugs




# PT Participant Summary & Evaluation Reports (Continued

Graph lists three consecutive mailings

### of each analyte

- Could help identify bias, shifts, or trends
- May be used to troubleshoot and evaluate whether results will be within or outside the limits of acceptability with new (tighter) grading criteria

-	Plot of the Relative Distan Target as Percentage							
	Survey	-100						
d)	C-C 2021 C-B 2021 C-A 2021	-100 -80 -60 -40 -2 x: Result is outs						
-	C-C 2021 C-B 2021 C-A 2021	-100 -80 -60 -40 -2						
	C-C 2021 C-B 2021 C-A 2021	-100 -80 -60 -40 -2						
-	C-C 2021 C-B 2021 C-A 2021	-100 -80 -60 -40 -2						



## **PT/EQA Troubleshooting Guide**

- Accessible from the PT resources on cap.org
  - Includes guidelines for monitoring PT/EQA performance using the evaluation graphs. Ο

LEARN



### 4. Learn

Review and interpret reports and implement and document corrective action for issues.

- Troubleshooting Guide for PT/EQA Data
- PT/EQA Exception Investigation Worksheet
- Performing a Self-Evaluation When PT is Not Graded A
- Root Cause Analysis Poster
- Root Cause Analysis Check Sheet A
- Why Proficiency Testing, Education and Insights (video)
- Proficiency Testing Participant Summary and Evaluation Resource



PATHOLOGISTS	
Troubleshooting Guide for Proficiency Testing/External Quality Assessment Data	
@ 2022 Callipy of American Phillippin, African assessed. any any	



# **Examples Illustrating Criteria Changes**

© College of American Pathologists.

### 26 June 2024

30


## Potassium: Current vs. New Criteria


### Potassium evaluated at target value +/- 0.5 mmol/L (current criteria)

Potassiu	CHM-06	6.3	6.33	0.07	274	-0.5	5.8	6.9	Acceptable		
mmol/L	CHM-07	3.3	3.33	0.05	275	-0.7	2.8	3.9	Acceptable	C-B 2023	
ION SELECT ELECT DIL	CHM-08	5.2	5.18	0.05	272	+0.4	4.6	5.7	Acceptable	C-A 2023	<b>,</b>
SIEMENS DIMENSION	CHM-09	5.0	4.95	0.06	274	+0.8	4.4	5.5	Acceptable	C-C 2022	
	CHM-10	6.8	6.80	0.07	273	-0.1	6.3	7.4	Acceptable		-100 -80 -60 -40 -20 0
									-		

### Same laboratory – C-B 2023 evaluated at target value +/- 0.3 mmol/L (new criteria)

Test		Evaluation and Comparative Method Statistics							Plot of the Relative Distance of You		
Unit of Measure		Your			No. of	L	imits of A	cceptability	Y Your	Targ	et as Percentages of allow
Peer Group	Specimen	Result	Mean	S.D.	Labs	S.D.I	Lower	Upper	Grade	Survey	-100Mean
Potassium, serum	CHM-06	6.3	6.33	0.07	274	-0.5	6.0	6.7	Acceptable		
mmol/L	CHM-07	3.3	3.33	0.05	275	-0.7	3.0	3.7	Acceptable	C-B 2023	
ION SELECT ELECT DIL	CHM-08	5.2	5.18	0.05	272	+0.4	4.8	5.5	Acceptable	C-A 2023	7
SIEMENS DIMENSION	CHM-09	5.0	4.95	0.06	274	+0.8	4.6	5.3	Acceptable	C-C 2022	
	CHM-10	6.8	6.80	0.07	273	-0.1	6.5	7.2	Acceptable		-100-80-60-40-20 0 2
									-		





## Hemoglobin & Hematocrit: Current vs. New Criteria

### Hemoglobin evaluated at target value +/- 7% (current criteria)

	FH9-01	5.7	5.75	0.08	98	-0.7	5.3	6.2	Acceptable							_
g/dL	FH9-02	17.9	18.45	0.21	98	-2.6	17.1	19.8	Acceptable	FH9-A 2024						1
	FH9-03	5.9	5.94	0.08	99	-0.5	5.5	6.4	Acceptable	FH9-C 2023				-	_	1
	FH9-04	15.7	16.17	0.19	98	-2.5	15.0	17.4	Acceptable	FH9-B 2023						1
	FH9-05	12.2	12.41	0.13	97	-1.5	11.5	13.3	Acceptable		100 -80 -60	-40 -20 0	20 4	-0 -00	80 1	00

### Same laboratory FH9-A 2024 evaluated at target value +/- 4% (new criteria)

Test		E	valuation a	Plot of the Relative Distance of Your Results from										
Unit of Measure Peer Group	Your				No. of	1	imits of A	cceptabilit	y Your	Target as Percentages of allowed Deviation				
reer Group	Specimen	Result	Mean	S.D.	Labs	S.D.I	Lower	Upper	Grade	Survey	-100Hean+100			
Hemoglobin	FH9-01	5.7	5.75	0.08	98	-0.7	5.5	6.0	Acceptable					
g/dL	FH9-02	17.9	18.45	0.21	98	-2.6	17.7	19.2	Acceptable	FH9-A 2024				
SYSMEX XN-SERIES RL AP	FH9-03	5.9	5.94	0.08	99	-0.5	5.7	6.2	Acceptable	FH9-C 2023 FH9-B 2023				
	FH9-04	15.7	16.17	0.19	98	-2.5	15.5	16.9	Acceptable					
	FH9-05	12.2	12.41	0.13	97	-1.5	11.9	13.0	Acceptable		-100-80-60-40-20 0 20 40 60 80 100			

### Hematocrit evaluated at target value +/- 6% (current criteria)


Hematocrit	FH9-01	16.70	16.887	0.350	97	-0.5	15.87	17.90	Acceptable					
%	FH9-02	50.10	51.878	0.877	98	-2.0	48.76	55.00	Acceptable	FH9-A 2024				
SYSMEX XN-SERIES RL AP	FH9-03	16.90	16.980	0.319	99	-0.3	15.96	18.00	Acceptable	FH9-C 2023				
	FH9-04	43.90	44.908	0.705	98	-1.4	42.21	47.61	Acceptable	FH9-B 2023				
	FH9-05	34.80	35.153	0.615	98	-0.6	33.04	37.27	Acceptable		-100-80 -60 -40 -20 0	20 40	60 E0 10	50

### Same laboratory FH9-A 2024 evaluated at target value +/- 4% (new criteria)

Hematocrit		FH9-01	16.70	16.887	0.350	97	-0.5	16.21	17.57	Acceptable							_
%		FH9-02	50.10	51.878	0.877	98	-2.0	49.80	53.96	Acceptable	FH9-A 2024						
SYSMEX XN-	SERIES RL AP	FH9-03	16.90	16.980	0.319	99	-0.3	16.30	17.66	Acceptable	FH9-C 2023						
		FH9-04	43.90	44.908	0.705	98	-1.4	43.11	46.71	Acceptable	FH9-B 2023			3			
		FH9-05	34.80	35.153	0.615	98	-0.6	33.74	36.56	Acceptable		-100 -80	-60 -40 -20	0 20	40	60 BC	1.10











## Impact on CAP Customers

© College of American Pathologists.

## Impact on CAP Customers: Accreditation

- CAP accredited laboratories that perform high-sensitivity cardiac troponin I or T testing are required to enroll in high sensitivity cardiac troponins PT to meet 2025 accreditation requirements.
- Laboratories that use accuracy-based proficiency testing for hemoglobin A1c will be required to evaluate results based on acceptable performance criteria of + 6% in 2025. Therefore, the CAP will provide two evaluations starting with the GH5-A 2025 mailing to meet CLIA (Target) value <u>+</u> 8%) and CAP checklist (Target value <u>+</u> 6%) requirements.

## Impact on CAP Customers: PT Enrollment

- Impact expected to be minimal
- Some programs reconfigured to meet CLIA requirements
  - **Five specimens, three times/year** 0
  - Exception: mycobacteriology, two events/year 0

## Impact on CAP Customers: PT Enrollment

- CAP will pre-populate customer order forms with the recommended program during the order renewal process, based on order history
- Review your 2025 order renewal form carefully
- CAP accredited laboratories: PT enrollment will be audited in early 2025 for analytes that require enrollment and participation to ensure compliance





# **Microbiology Changes**


© College of American Pathologists.

## 26 June 2024

37

## **Overview: Changes in Microbiology** and Subspecialties

- Bacteriology
- Mycobacteriology
- Mycology
- Parasitology
- Virology



# Bacteriology

© College of American Pathologists.

# **Bacteriology**

- Gram stain will now include bacterial morphology
  - Both stain and morphology results will be submitted Ο to CMS
- **Direct bacterial antigen detection and** bacterial toxin detection will be reported to CMS
- Included as reporting option: Detection of the presence or absence of bacteria without identification

2025 Criteria for Acceptable Performance			
Analyte or test	New CMS criteria for acceptable performance to be implemented on January 1, 2025	Comments	
Antimicrobial susceptibility testing	80% participant or referee consensus and CLSI guidelines for 2 graded challenges	Number of challenges increased to 2 <b>graded</b> per mailing; ungraded educational challenge will not be offered	
Bacterial antigen detection	80% participant or referee consensus	No change	
Bacterial toxin detection	80% participant or referee consensus	New CMS regulated analyte	
Bacterial identification	80% participant or referee consensus	No change	
Gram stain reaction	80% participant or referee consensus	No change	
Gram stain morphology	80% participant or referee consensus	New CMS regulated analyte, see below*	

Analytes regulated for proficiency testing appear in **bold** type.

\*Effective January 1, 2025, Gram stain result reporting to CMS will include both reaction and morphology.

## Ashle B

# Bacteriology

- Laboratories must detect and identify organisms for PT to the highest level that the laboratory reports results on patient specimens
  - At least 25% of samples must be mixtures of the principal pathogen and appropriate normal flora (change from 50%)
- Two specimens/mailing will be included for antimicrobial susceptibility testing (AST)
  - Program will include gram-positive and gram-negative organisms that have a predetermined 0 pattern of susceptibility to the common antimicrobial agents

26 June 2024

41

# Mycobacteriology

© College of American Pathologists.

26	June
	2024

## **Mycobacteriology**

- This subspecialty includes five specimens, two mailings per year
- Included as a reporting option: Detection of the presence or absence of mycobacteria without identification
- Laboratory must detect and identify organisms to the highest level that the laboratory reports results on patient specimens
- Molecular identification of mycobacteria is allowed

# **Mycobacteriology**

- At least 25% of the samples must be mixtures of principal mycobacteria appropriate normal flora (change from 50%)
- The Antimicrobial Susceptibility Testing (AST) challenge is removed as a CMSregulated test
  - However, CAP will continue to include two AST 0 challenges as currently offered to meet the regulatory requirement for verifying test accuracy at least 2X per

2025 Criteria for Acce	
Analyte or test	New CMS criteria for a performance to be imple January 1, 202
Antimycobacterial susceptibility testing (AST)	80% participant consensus
Mycobacteria identification	80% participant or referee con
Acid-fast smear	80% participant or referee con

Analytes regulated for proficiency testing appear in **bold** type.

\*Effective January 1, 2025, AST will no longer be CMS regulated. The CAP will continue to offer AST challenges to meet alternative performance assessment requirements.

vear. © College of American Pathologists

## able Performance

cceptable mented on 5	Comments
	See below*
sensus	No change
sensus	No change



## Mycology

- Now included: fungal antigen detection category for CMS reporting
- Detection of the presence or absence of fungi and aerobic actinomycetes without identification
- Laboratory must detect and identify the organisms to highest level that the laboratory reports results on patient specimens
- At least 25% of samples must be mixtures of the principal pathogen and appropriate normal flora (change from 50%)
- Molecular identification of fungi is allowed

# **Mycology**

- CMS will not require antifungal susceptibility testing for mycology as originally proposed
- However, CAP will continue to offer antifungal susceptibility challenges in its mycology programs to meet the regulatory requirement for verifying test accuracy at least 2X per year.

Mycology and Aerobic Actinomycetes (F) 0

Yeast (F1) 0

# Parasitology

© College of American Pathologists.

# **Parasitology**

- **Direct parasite antigen detection category is now included for CMS** reporting
- A laboratory must detect and identify parasites to the highest level
- Molecular identification of parasites is allowed



## 26 June 2024

50

## Virology

- Laboratory must detect and identify the viruses to the highest level that the laboratory reports results on patient specimens
- No other changes



## **Customer Resources**

- Effective in the 2024 A mailings: detailed information regarding all the changes in each PT Participant Summary Report
- May 2024 CAP Today Q&A article
- Cap.org Regulatory News and Updates webpage

